TY - JOUR T1 - The longitudinal kinetics of antibodies in COVID-19 recovered patients over 14 months JF - medRxiv DO - 10.1101/2021.09.16.21263693 SP - 2021.09.16.21263693 AU - T. Eyran AU - A. Vaisman-Mentesh AU - Y. Dror AU - L. Aizik AU - A. Kigel AU - S. Rosenstein AU - Y. Bahar AU - D. Taussig AU - R. Tur-Kaspa AU - T. Kournos AU - D. Markovitch AU - D. Dicker AU - Y. Wine Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/21/2021.09.16.21263693.abstract N2 - Here, we describe the longitudinal kinetics of the serological response in COVID-19 recovered patients over the period of 14 months. The antibody kinetics in a cohort of 200 recovered patients with 89 follow up samples at 2-4 visits reveal that RBD-specific antibodies decay over the period of 14 month following the onset of symptoms. The decay rate is associated with the robustness of the response thus, recovered patients that exhibit elevated antibody levels at the first visit, experience faster decay. We further explored the longitudinal kinetics differences between recovered patients and naïve BNT162b2 vaccinees. We found a significantly faster decay in naïve vaccinees compared to recovered patients suggesting that the serological memory following natural infection is more robust compared to vaccination. Our data highlights the differences between serological memory induced by natural infection vs. vaccination, facilitating the decision making in Israel regarding the 3rd dose vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Israel Ministry of Health (MOH) grant #3-17162Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Tel Aviv University institutional review board (IRB): 2938-3, 406-2, 1281-4 Hasharon Hospital, Rabin Medical Center under ethical approval number 0265-20All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author [D.D. or W.Y.]. The data are not publicly available due to the fact that they contain information that could compromise research participant privacy/consent. ER -